序號

藥物名稱

在研公司

目前較高研究階段

1

DKF-313

Dong Kook Pharmaceutical Co Ltd

Phase 1 Clinical

2

insulin lispro biosimilar

Sanofi

Phase 3 Clinical

3

dupilumab

Regeneron Pharmaceuticals Inc; Sanofi

Phase 3 Clinical

4

ibrutinib

Janssen Biotech Inc; Johnson & Johnson; Pharmacyclics Inc

Launched

5

MEDI-6469 + tremelimumab (solid tumor)

MedImmune LLC

Phase 1 Clinical

6

diphenylcyclopropenone (gel)

RXi Pharmaceuticals Corp

Phase 2 Clinical

7

AKP-11

Akaal Pharma Pty Ltd

Phase 1 Clinical

8

SAR-408701

Sanofi

Phase 2 Clinical

9

durvalumab

AstraZeneca plc; MedImmune LLC

Phase 3 Clinical

10

namilumab

Takeda Pharmaceuticals International GmbH

Phase 2 Clinical

11

GZ-402666

Genzyme Corp

Phase 3 Clinical

12

moxifloxacin hydrochloride + triamcinolone acetonide (LessDrop combination, ophthalmic formulation)

Imprimis Pharmaceuticals Inc

Clinical

13

prednisolone acetate + moxifloxacin hydrochloride (eye drop formulation)

Imprimis Pharmaceuticals Inc

Clinical

14

demcizumab

Celgene Corp; OncoMed Pharmaceuticals Inc

Phase 2 Clinical

15

nivolumab

Bristol-Myers Squibb Co; Medarex Inc; Ono Pharmaceutical Co Ltd

Launched

16

BBI-5000

Brickell Biotech Inc

Phase 1 Clinical

17

ASP-6858

Astellas Pharma Inc

Phase 1 Clinical

18

ASP-5094

Astellas Pharma Inc

Phase 1 Clinical

19

BBI-4000

Brickel

厚樸方舟2012年進入海外醫(yī)療領(lǐng)域，總部位于北京，建立了由全球權(quán)威醫(yī)學(xué)專家組成的美日名醫(yī)集團，初個擁有日本政府官方頒發(fā)的海外醫(yī)療資格的企業(yè)。如果您有海外就醫(yī)的需要，請撥打免費熱線400-086-8008進行咨詢！

本文由厚樸方舟編譯，版權(quán)歸厚樸方舟所有，轉(zhuǎn)載或引用本網(wǎng)版權(quán)所有之內(nèi)容須注明"轉(zhuǎn)自厚樸方舟官網(wǎng)（m.wyaoyao.cn）"字樣，對不遵守本聲明或其他違法、惡意使用本網(wǎng)內(nèi)容者，本網(wǎng)保留追究其法律責(zé)任的權(quán)利。

上一篇：中國患者如何快速獲得日本和美國的丙肝新藥 下一篇：乳腺癌患者的福音—晚期乳癌的新藥IBRANCE獲批